CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Evaluate the ability to predict survival benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC), and
The MAC9 (S0307) PHASE III TRIAL OF BISPHOSPHONATES AS ADJUVANT THERAPY FOR PRIMARY BREAST CANCER trial has been permanently closed.
PURPOSE: This randomized phase III trial studied zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
CCTG is currently recruiting for a Regulatory Affairs Team Leader and a Cancer Research Monitor/Auditor to join our central offices at Queen's University in Kingston Ontario.
A new nation-wide study examines how COVID-19 is impacting cancer patients and survivors
March 12, 2021 By Jennifer Friesen
There’s no question that 2020 was a challenging year. Today, the effects of COVID-19 continue to echo around the world, impacting people’s lives, livelihoods and social connections.
In addition to navigating all this global uncertainty, an estimated 225,000 Canadians also faced a cancer diagnosis last year.
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY12 Clinical Trial" has been published in Current Oncology and is available online: https://www.mdpi.com/1718-7729/28/2/119
It is official we are going virtual so save the dates April 22 – 25!
